Syndax Pharmaceuticals Inc., a Waltham company that looks to market treatments for breast and lung cancers, said Tuesday that it has secured a $26.6 million Series B financing.
Participating investors included Domain Associates, MPM Capital, Forward Ventures, and RusnanoMedInvest, Waltham-based Syndax said in a press release. MPM Capital has an office in Boston.
The company’s lead drug candidate is called entinostat, and the hope is that entinostat can be part of a drug combination that can be effective against breast and lung cancers that become resistant to traditional treatments. Entinostat is about to enter late-stage clinical testing.
In a statement, Syndax chief executive Arlene M. Morris said: “Entinostat represents the most advanced clinical program of an epigenetic therapy in solid
tumors. We have a unique opportunity to help a patient population where safe and effective treatments capable of extending survival are needed desperately. The Series B financing enables us to continue to advance entinostat toward registration, where we believe the opportunity in breast cancer and lung cancer alone exceeds $2 billion.’’